8:00 am
Virtual Coffee & Online Registration
8:45 am Chair’s Opening Remarks
9:00 am An In-Depth Overview of Current Research Strategies for Glioblastoma & Barriers to Progress
Synopsis
- Overview of changes in the classification and definition of glioblastoma
- Summary of the major therapeutic strategies currently under
development - Discuss barriers to progress and strategies to address these
9:30 am Overcoming the Blood Brain Drug Delivery Hurdle with Tumor Treating Fields (TTFields)
Synopsis
- Evaluate the effect of TTFields on an in vitro blood brain barrier (BBB) model
- Investigate TTFields induced BBB opening in vivo
- Discuss the potential of TTFields to improve treatment of glioblastoma and other CNS diseases by opening the BBB
9:50 am I’m Still Here – A Long-Term Survivor’s Perspective
Synopsis
- Explore a patient’s GBM story and drug treatments
- Learn how to diagnose GBM patients and what’s involved
- Deep dive into OurBrainBank – a patient-driven movement to turn glioblastoma from terminal to treatable
IMMUNO-ONCOLOGY & THERAPY
10:20 am Optimize the Role of Immunotherapy for Treatment of Glioblastoma
Synopsis
- Outline the historical and current understanding of the mechanisms of
immune responses against glioblastoma - Discuss the common challenges of designing and evaluating clinical
trials of immunotherapy for glioblastoma - Elucidate the considerations of timing, sequence, and tumor/patient
heterogeneity in developing combination immunotherapy/vaccine trials
for glioblastoma
10:50 am MDNA55, an IL4-Guided Toxin in Recurrent GBM: Phase 2b Results & Use of an External Control Arm in a Registration Trial
Synopsis
- Updated results from the Phase 2b clinical trial: results show improved 2-year survival rate and long-term tumor control (progression-free survival)
- Use of a propensity matched External Control Arm (ECA) demonstrates potential utility for go/no go decisions and reduces risk in a registration trial
- Presentation of a novel hybrid-design incorporating an ECA in a planned recurrent GBM registration trial
11:10 am
Morning Break & Virtual Speed Networking
VACCINES
11:40 am An Exclusive Update on Neoantigen Vaccination for Glioblastoma
Synopsis
- Describe rationale for targeting neoantigens for anti-tumor vaccination
- Summarize therapeutic development of neoantigen vaccination for
oncology to date - Overview results of neoantigen vaccination application for glioblastoma
- Enhance next steps to optimize neoantigen vaccination for glioblastoma
12:10 pm Examine the Absolute Utilization of Vaccine Immunotherapy to Treat Glioblastoma
Synopsis
- Explore immunotherapy with vaccines that can be used to treat GBM
- Evaluate personalized vaccines and off-the-shelf vaccines
- Discuss use of vaccines in combination treatments for GBM
12:40 pm Adaptive T-cell Immunotherapy for Newly Diagnosed Glioblastoma: Using Targeted Antigen Presentation to Enhance Immune Responses
Synopsis
- Studies using a intracellular targeting technology have shown promising clinical responses in newly diagnosed GBM subjects
- Phase I median overall survival for treated subjects was >41 months in newly diagnosed GBM in a small cohort of patients (N=21)
- Animal modeling using pDNA in a cell-free approach may provide an alternative to cell therapy and potentially expand the candidate patient population
12:50 pm
Lunch Break & Virtual Networking
1:50 pm PANEL DISCUSSION: Evaluate the Current Challenges, Approaches and Opportunities in Treating Glioblastoma
Synopsis
- A year on from the inaugural GBM Drug Development meeting: What have we learnt?
- How can drug developers cut to the real barriers, and debate what is truly required to break through to successful treatments for GBM?
- The impact of COVID-19 and its repercussions on existing clinical trials
2:35 pm Exhausted T-cells for GBM Immunotherapy: An Exclusive Look at Fresh GBM Clinical Trial Results
Synopsis
- Discuss concept of exhaustion in T-cells
- Examine GBM specific immunosuppression
- Evaluate results from recent Glioblastoma patient clinical trials
3:05 pm Empower the Immune System to Treat Glioblastoma: DNA as Medicine
Synopsis
- Explore DNA medicines that have the potential to create robust,
antigen-specific T cell responses - Evaluate Inovio’s DNA medicine, INO-5401 has promising, early data in
GBM showing early efficacy, and immunogenicity - Discuss Inovio’s DNA medicine, its technology, and other promising
approaches to GBM therapy will be discussed
3:35 pm Updated Clinical Results in Recurrent Glioblastoma for VBI1901 – A Therapeutic Vaccine Targeting CMV-Associated Cancers
Synopsis
- Explore VBI-1901 targets CMV-antigens that are highly expressed in
glioblastoma - Study a Phase I/II study that has demonstrated improved OS among
vaccine responders - Assess a novel biomarker may predict patients most likely to derive
clinical benefit from VBI-1901
4:05 pm
Afternoon Break & Virtual Networking
4:35 pm SurVaxM, First-of-its-Kind: A Survivin-Targeted Vaccine for Glioblastoma
Synopsis
- Explore how SurVaxM induces strong immune responses involving more
than one arm of the immune system - Assess how strong immune responses to SurVaxM are associated with
longer survival - Discuss OS and PFS, and how they may be extended in patients with
newly diagnosed glioblastoma by treatment with SurVaxM
5:05 pm Special Look At Phase 1b Imvax Study to Assess the Safety and Efficacy of IGV-001
Synopsis
- Explore highest exposure cohort yielded significantly higher proinflammatory cytokine serum levels; by 23rd patient, clear that clinical and radiographic responses were superior in this cohort and protocol amended for ethical reasons to stop randomization.
- Deep dive with data lock, highest exposure cohort exhibiting significant improvement in both PFS and OS over historical controls.
- Study methylated subgroup manifesting a 3-fold improvement in mPFS with mOS not yet reached
5:35 pm A Complete Review of Autologous Dendritic Cells Loaded with Antigens from Self-Renewing Autologous Glioblastoma Cells
Synopsis
- Examine the importance of neoantigens and antigens from tumor initiating cells as an excellent source of antigens for patient-specific vaccines
- Evaluate the advantage of injections of autologous dendritic cells with tumor antigens ex vivo compared to injecting tumor antigens
- A look at enrollment completed for a phase II trial testing for a vaccine, along with chemotherapy and radiation therapy for primary GBM
6:05 pm PANEL DISCUSSION: An Overview of Emerging Therapeutic Targets
Synopsis
- Examine the current treatment options and emerging targeted therapies
- If targeted therapies show limited efficacy as single agents, can the combination of several targeted therapies be of benefit to GBM patients?
- Additional research is urgently required to identify therapeutic targets in GBM: How can the industry design novel therapeutic strategies for the treatment of GBM?
6:50 pm
Chair’s Closing Remarks
7:00 pm
End of Day One of the 2nd Glioblastoma Drug Development Summit
